Neumora Therapeutics is a clinical-stage biopharmaceutical company. Co. has scaled its therapeutic pipeline, which consists of seven clinical and preclinical neuroscience programs that target mechanisms of action for a range of neuropsychiatric disorders and neurodegenerative diseases. Co.'s primary product candidate, navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist that is being developed for the treatment of major depressive disorder (MDD). Co. is initiating a Phase 3 program for navacaprant monotherapy in patients with moderate to severe MDD. The NMRA average annual return since 2023 is shown above.
The Average Annual Return on the NMRA average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NMRA average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NMRA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|